10-KPeriod: FY2008

ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2008

Filed March 2, 2009For Securities:ALNY

Summary

This 10-K filing for Alnylam Pharmaceuticals, Inc. (ALNY) as of March 2, 2009, provides a snapshot of the company during a critical development phase. The company is focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. While the filing details significant research and development activities, investors should note that Alnylam is an early-stage biopharmaceutical company with no approved products and is heavily reliant on its pipeline and collaborations for future revenue. The financial statements indicate substantial operating losses, as is typical for companies at this stage of development, underscoring the inherent risks associated with investing in biotechnology. Key to Alnylam's strategy is its robust intellectual property portfolio and its partnerships with major pharmaceutical companies, which provide crucial funding and expertise. The risk factors section highlights the significant challenges ahead, including the inherent uncertainties of drug development, regulatory approvals, intellectual property protection, and market competition. Investors should carefully assess these risks in conjunction with the company's long-term growth potential derived from its innovative RNAi platform.

Financial Highlights

24 data points
Beta

Revenue

$96.16M

Net Income

-$26.25M

-27.3% Net Margin

Cash & Equivalents

$191.79M

Free Cash Flow

$54.73M

Financial Statements
Beta
Revenue$96.16M
R&D Expenses$96.88M
Operating Expenses$124.00M
Operating Income-$27.84M
Interest Expense$872K
Net Income-$26.25M

Key Highlights

  • 1Alnylam Pharmaceuticals is focused on the development of RNA interference (RNAi) therapeutics, a novel class of drugs.
  • 2The company has a strong intellectual property portfolio related to RNAi technology.
  • 3Alnylam has entered into significant collaborations and license agreements with major pharmaceutical companies to advance its pipeline.
  • 4As of the filing date, Alnylam has no approved products and generates no product revenue, relying on upfront payments, milestones, and research funding from partners.
  • 5The company incurred significant operating losses, reflecting its substantial investment in research and development.
  • 6The risk factors section details the inherent uncertainties and challenges in drug development, regulatory approval, and commercialization.
  • 7Key development programs are in early to mid-stage clinical trials, indicating a long path to potential market entry.

Frequently Asked Questions

Alnylam Pharmaceuticals' primary business focus is on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics, which are a novel class of drugs designed to leverage the body's natural gene silencing pathway.

No, as of the filing date of March 2, 2009, Alnylam Pharmaceuticals had no approved products on the market and therefore generated no product revenue.

Alnylam primarily funds its operations and development through upfront payments, milestone payments, and research funding received from its strategic collaborations and license agreements with larger pharmaceutical companies, as well as through equity financings.

Major risks include the significant uncertainties inherent in the drug development process, the need for successful clinical trials and regulatory approvals, potential intellectual property disputes, competition from other therapeutic approaches, and the company's reliance on its partners and its ability to manage substantial operating losses.